×
VivoSim Labs EBIT 2011-2025 | VIVS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
VivoSim Labs ebit from 2011 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
VivoSim Labs EBIT 2011-2025 | VIVS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
VivoSim Labs ebit from 2011 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231.3B
Amgen (AMGN)
$153.3B
Gilead Sciences (GILD)
$137.2B
Vertex Pharmaceuticals (VRTX)
$96.3B
Bristol Myers Squibb (BMY)
$92.3B
CSL (CSLLY)
$83.7B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$60.4B
Alnylam Pharmaceuticals (ALNY)
$57B
Argenex SE (ARGX)
$41.1B
BioNTech SE (BNTX)
$26.8B
Royalty Pharma (RPRX)
$20.8B
Insmed (INSM)
$20.7B
Biogen (BIIB)
$18.7B
Incyte (INCY)
$15.3B
Illumina (ILMN)
$14.7B
Genmab (GMAB)
$14.6B
Genmab (GNMSF)
$14.3B
Ascendis Pharma (ASND)
$11.6B
BioMarin Pharmaceutical (BMRN)
$11.4B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Moderna (MRNA)
$10.4B
Exelixis (EXEL)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Exact Sciences (EXAS)
$8.2B
Bio-Techne Corp (TECH)
$7.9B
Roivant Sciences (ROIV)
$7.9B
Halozyme Therapeutics (HALO)
$7.7B